{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T16:24:16Z","timestamp":1789835056044,"version":"4.0.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,8,6]],"date-time":"2019-08-06T00:00:00Z","timestamp":1565049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,8,6]],"date-time":"2019-08-06T00:00:00Z","timestamp":1565049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Obes"],"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background\/Objectives<\/jats:title>\n            <jats:p>Non-alcoholic fatty liver disease (NAFLD) causes a wide spectrum of liver damage, from simple steatosis (SS) to cirrhosis. SS and non-alcoholic steatohepatitis (NASH) cannot be distinguished by clinical or laboratory features. Dysregulation of the gut microbiota is involved in NASH pathogenesis. The aim of this study was to assess the relationship between microbiota-derived metabolites and the degrees of NAFLD; also, to investigate whether these metabolites could be included in a panel of NASH biomarkers.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Subjects\/Methods<\/jats:title>\n            <jats:p>We used liquid chromatography coupled to triple-quadrupole-mass spectrometry (LC-QqQ) analysis to quantify choline and its derivatives, betaine, endogenous ethanol, bile acids, short-chain fatty acids and soluble TLR4 in serum from women with normal weight (<jats:italic>n<\/jats:italic>\u2009=\u200929) and women with morbid obesity (MO) (<jats:italic>n<\/jats:italic>\u2009=\u200982) with or without NAFLD. We used real-time polymerase chain reaction (RT-PCR) analysis to evaluate the hepatic and intestinal expression level of all genes studied (TLR2, TLR4, TLR9, LXR\u03b1, SREBP1C, ACC1, FAS, PPAR\u03b1, CPT1\u03b1, CROT, SREBP2, ABCA1, ABCG1 and FXR in the liver; TLR2, TLR4, TLR5, TLR9, GLP-1R, DPP-4, FXR and PPAR\u0263 in the jejunum) in 82 women with MO with normal liver histology (NL, <jats:italic>n<\/jats:italic>\u2009=\u200929), SS (<jats:italic>n<\/jats:italic>\u2009=\u200932), and NASH (<jats:italic>n<\/jats:italic>\u2009=\u200921).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Hepatic FAS, TLR2, and TLR4 expression were overexpressed in NAFLD patients. TLR2 was overexpressed in NASH patients. In women with MO with NAFLD, we found upregulation of intestinal TLR9 expression and downregulation of intestinal FXR expression in women with NASH. Circulating TMAO, glycocholic acid and deoxycholic acid levels were significantly increased in NAFLD patients. Endogenous circulating ethanol levels were increased in NASH patients in comparison to those in SS patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>These findings suggest that the intestine participates in the progression of NAFLD. Moreover, levels of certain circulating microbiota-related metabolites are associated with NAFLD severity and could be used as a \u201cliquid biopsy\u201d in the noninvasive diagnosis of NASH.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1038\/s41366-019-0430-0","type":"journal-article","created":{"date-parts":[[2019,8,6]],"date-time":"2019-08-06T16:04:02Z","timestamp":1565107442000},"page":"875-885","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":62,"title":["Circulating microbiota-derived metabolites: a \u201cliquid biopsy?"],"prefix":"10.1038","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1924-9231","authenticated-orcid":false,"given":"Gemma","family":"Aragon\u00e8s","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Colom-Pellicer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Aguilar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Guiu-Jurado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salom\u00e9","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F\u00e0tima","family":"Sabench","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Antonio Porras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Riesco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Del Castillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crist\u00f3bal","family":"Richart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Auguet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,6]]},"reference":[{"key":"430_CR1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease\u2014meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73\u201384.","journal-title":"Hepatology"},{"key":"430_CR2","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1002\/hep.29085","volume":"65","author":"PS Dulai","year":"2017","unstructured":"Dulai PS, Singh S, Patel J, Soni M, Prokop LJ, Younossi Z, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology. 2017;65:1557\u201365.","journal-title":"Hepatology"},{"key":"430_CR3","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1002\/hep.29721","volume":"68","author":"ZM Younossi","year":"2018","unstructured":"Younossi ZM, Loomba R, Anstee QM, Rinella ME, Bugianesi E, Marchesini G, et al. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis. Hepatology. 2018;68:349\u201360.","journal-title":"Hepatology"},{"key":"430_CR4","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jhep.2017.11.014","volume":"68","author":"F Marra","year":"2018","unstructured":"Marra F, Svegliati-Baroni G. Lipotoxicity and the gut-liver axis in NASH pathogenesis. J Hepatol. 2018;68:280\u201395.","journal-title":"J Hepatol"},{"key":"430_CR5","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","volume":"65","author":"E Buzzetti","year":"2016","unstructured":"Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016;65:1038\u201348.","journal-title":"Metabolism"},{"key":"430_CR6","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1093\/advances\/nmy078","volume":"10","author":"A Cuevas-Sierra","year":"2019","unstructured":"Cuevas-Sierra A, Ramos-Lopez O, Riezu-Boj JI, Milagro FI, Martinez JA. Diet, gut microbiota, and obesity: links with host genetics and epigenetics and potential applications. Adv Nutr. 2019;10:S17\u201330.","journal-title":"Adv Nutr"},{"key":"430_CR7","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1007\/s10620-016-4045-1","volume":"61","author":"RM Abdou","year":"2016","unstructured":"Abdou RM, Zhu L, Baker RD, Baker SS. Gut microbiota of nonalcoholic fatty liver disease. Dig Dis Sci. 2016;61:1268\u201381.","journal-title":"Dig Dis Sci"},{"key":"430_CR8","doi-asserted-by":"publisher","first-page":"300","DOI":"10.3390\/ijms17030300","volume":"17","author":"X He","year":"2016","unstructured":"He X, Ji G, Jia W, Li H. Gut microbiota and nonalcoholic fatty liver disease: insights on mechanism and application of metabolomics. Int J Mol Sci. 2016;17:300.","journal-title":"Int J Mol Sci"},{"key":"430_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2019\/8507583","volume":"2019","author":"G Aragon\u00e8s","year":"2019","unstructured":"Aragon\u00e8s G, Gonz\u00e1lez-Garc\u00eda S, Aguilar C, Richart C, Auguet T. Gut microbiota-derived mediators as potential markers in nonalcoholic fatty liver disease. Biomed Res Int. 2019;2019:1\u201310.","journal-title":"Biomed Res Int"},{"key":"430_CR10","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1177\/2050640618804444","volume":"6","author":"M Rau","year":"2018","unstructured":"Rau M, Rehman A, Dittrich M, Groen AK, Hermanns HM, Seyfried F, et al. Fecal SCFAs and SCFA-producing bacteria in gut microbiome of human NAFLD as a putative link to systemic T-cell activation and advanced disease. United Eur Gastroenterol J. 2018;6:1496\u2013507.","journal-title":"United Eur Gastroenterol J"},{"key":"430_CR11","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1111\/j.1365-2672.2010.04922.x","volume":"110","author":"E Naito","year":"2011","unstructured":"Naito E, Yoshida Y, Makino K, Kounoshi Y, Kunihiro S, Takahashi R, et al. Beneficial effect of oral administration of Lactobacillus casei strain Shirota on insulin resistance in diet-induced obesity mice. J Appl Microbiol. 2011;110:650\u20137.","journal-title":"J Appl Microbiol"},{"key":"430_CR12","unstructured":"Junker AE. The role of incretin hormones and glucagon in patients with liver disease. Dan Med J. 2017;64. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28552096."},{"key":"430_CR13","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.dld.2014.02.010","volume":"46","author":"V Giorgio","year":"2014","unstructured":"Giorgio V, Miele L, Principessa L, Ferretti F, Villa MP, Negro V, et al. Intestinal permeability is increased in children with non-alcoholic fatty liver disease, and correlates with liver disease severity. Dig Liver Dis. 2014;46:556\u201360.","journal-title":"Dig Liver Dis"},{"key":"430_CR14","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/jgh.13058","volume":"31","author":"S Kapil","year":"2016","unstructured":"Kapil S, Duseja A, Sharma BK, Singla B, Chakraborti A, Das A, et al. Small intestinal bacterial overgrowth and toll-like receptor signaling in patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2016;31:213\u201321.","journal-title":"J Gastroenterol Hepatol"},{"key":"430_CR15","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.jcmgh.2016.04.007","volume":"2","author":"L Etienne-Mesmin","year":"2016","unstructured":"Etienne-Mesmin L, Vijay-Kumar M, Gewirtz AT, Chassaing B. Hepatocyte Toll-like receptor 5 promotes bacterial clearance and protects mice against high-fat diet-induced liver disease. Cell Mol Gastroenterol Hepatol. 2016;2:584\u2013604.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"430_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/srep27849","volume":"6","author":"S Kim","year":"2016","unstructured":"Kim S, Park S, Kim B, Kwon J. Toll-like receptor 7 affects the pathogenesis of non-alcoholic fatty liver disease. Sci Rep. 2016;6:27849.","journal-title":"Sci Rep"},{"key":"430_CR17","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/nature10809","volume":"482","author":"J Henao-Mejia","year":"2012","unstructured":"Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ, Strowig T, et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature. 2012;482:179\u201385.","journal-title":"Nature"},{"key":"430_CR18","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3945\/an.114.007955","volume":"7","author":"JL Sherriff","year":"2016","unstructured":"Sherriff JL, O\u2019Sullivan TA, Properzi C, Oddo J-L, Adams LA. Choline, its potential role in nonalcoholic fatty liver disease, and the case for human and bacterial genes. Adv Nutr. 2016;7:5\u201313.","journal-title":"Adv Nutr"},{"key":"430_CR19","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.1002\/jcb.27635","volume":"120","author":"J Chen","year":"2019","unstructured":"Chen J, Thomsen M, Vitetta L. Interaction of gut microbiota with dysregulation of bile acids in the pathogenesis of nonalcoholic fatty liver disease and potential therapeutic implications of probiotics. J Cell Biochem. 2019;120:2713\u201320.","journal-title":"J Cell Biochem"},{"key":"430_CR20","doi-asserted-by":"publisher","first-page":"3318","DOI":"10.1007\/s10620-015-3776-8","volume":"60","author":"BC Ferslew","year":"2015","unstructured":"Ferslew BC, Xie G, Johnston CK, Su M, Stewart PW, Jia W, et al. Altered bile acid metabolome in patients with nonalcoholic steatohepatitis. Dig Dis Sci. 2015;60:3318\u201328.","journal-title":"Dig Dis Sci"},{"key":"430_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0096969","volume":"9","author":"J Chao","year":"2014","unstructured":"Chao J, Huo T-I, Cheng H-Y, Tsai J-C, Liao J-W, Lee M-S, et al. Gallic acid ameliorated impaired glucose and lipid homeostasis in high fat diet-induced NAFLD mice. PLoS ONE. 2014;9:e96969.","journal-title":"PLoS ONE"},{"key":"430_CR22","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1002\/hep.28572","volume":"65","author":"F Del Chierico","year":"2017","unstructured":"Del Chierico F, Nobili V, Vernocchi P, Russo A, Stefanis CD, Gnani D, et al. Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated meta-omics-based approach. Hepatology. 2017;65:451\u201364.","journal-title":"Hepatology"},{"key":"430_CR23","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.20701","volume":"41","author":"DE Kleiner","year":"2005","unstructured":"Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313\u201321.","journal-title":"Hepatology"},{"key":"430_CR24","doi-asserted-by":"publisher","first-page":"22173","DOI":"10.3390\/ijms151222173","volume":"15","author":"T Auguet","year":"2014","unstructured":"Auguet T, Berlanga A, Guiu-Jurado E, Martinez S, Porras JA, Aragon\u00e8s G, et al. Altered fatty acid metabolism-related gene expression in liver from morbidly obese women with non-alcoholic fatty liver disease. Int J Mol Sci. 2014;15:22173\u201387.","journal-title":"Int J Mol Sci"},{"key":"430_CR25","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1002\/hep.27695","volume":"61","author":"BM Arendt","year":"2015","unstructured":"Arendt BM, Comelli EM, Ma DWL, Lou W, Teterina A, Kim T, et al. Altered hepatic gene expression in nonalcoholic fatty liver disease is associated with lower hepatic n-3 and n-6 polyunsaturated fatty acids. Hepatology. 2015;61:1565\u201378.","journal-title":"Hepatology"},{"key":"430_CR26","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jhep.2009.12.044","volume":"53","author":"N Dhillon","year":"2010","unstructured":"Dhillon N, Walsh L, Kr\u00fcger B, Ward SC, Godbold JH, Radwan M, et al. A single nucleotide polymorphism of Toll-like receptor 4 identifies the risk of developing graft failure after liver transplantation. J Hepatol. 2010;53:67\u201372.","journal-title":"J Hepatol"},{"key":"430_CR27","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1053\/j.gastro.2010.03.052","volume":"139","author":"K Miura","year":"2010","unstructured":"Miura K, Kodama Y, Inokuchi S, Schnabl B, Aoyama T, Ohnishi H, et al. Toll-Like Receptor 9 Promotes Steatohepatitis by Induction of Interleukin-1\u03b2 in Mice. Gastroenterology. 2010;139:323\u2013.e7.","journal-title":"Gastroenterology"},{"key":"430_CR28","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1042\/CS20160838","volume":"131","author":"AR Mridha","year":"2017","unstructured":"Mridha AR, Haczeyni F, Yeh MM, Haigh WG, Ioannou GN, Barn V, et al. TLR9 is up-regulated in human and murine NASH: pivotal role in inflammatory recruitment and cell survival. Clin Sci. 2017;131:2145\u201359.","journal-title":"Clin Sci"},{"key":"430_CR29","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1126\/science.1179721","volume":"328","author":"M Vijay-Kumar","year":"2010","unstructured":"Vijay-Kumar M, Aitken JD, Carvalho FA, Cullender TC, Mwangi S, Srinivasan S, et al. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science. 2010;328:228\u201331.","journal-title":"Science"},{"key":"430_CR30","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1111\/liv.12442","volume":"35","author":"G Kanuri","year":"2015","unstructured":"Kanuri G, Ladurner R, Skibovskaya J, Spruss A, K\u00f6nigsrainer A, Bischoff SC, et al. Expression of toll-like receptors 1-5 but not TLR 6-10 is elevated in livers of patients with non-alcoholic fatty liver disease. Liver Int. 2015;35:562\u20138.","journal-title":"Liver Int"},{"key":"430_CR31","doi-asserted-by":"publisher","unstructured":"Chiu CC, Ching YH, Li YP, Liu JY, Huang YT, Huang YW, et al. Nonalcoholic fatty liver disease is exacerbated in high-fat diet-fed gnotobiotic mice by colonization with the gut microbiota from patients with nonalcoholic steatohepatitis. Nutrients. 2017;9. https:\/\/doi.org\/10.3390\/nu9111220.","DOI":"10.3390\/nu9111220"},{"key":"430_CR32","doi-asserted-by":"publisher","first-page":"207","DOI":"10.4161\/viru.23354","volume":"4","author":"K Kamdar","year":"2013","unstructured":"Kamdar K, Nguyen V, DePaolo RW. Toll-like receptor signaling and regulation of intestinal immunity. Virulence. 2013;4:207\u201312.","journal-title":"Virulence"},{"key":"430_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2017\/9624702","volume":"2017","author":"A Dlugosz","year":"2017","unstructured":"Dlugosz A, Zakikhany K, Acevedo N, D\u2019Amato M, Lindberg G. Increased expression of toll-like receptors 4, 5, and 9 in small bowel mucosa from patients with irritable bowel syndrome. Biomed Res Int. 2017;2017:1\u20137.","journal-title":"Biomed Res Int"},{"key":"430_CR34","doi-asserted-by":"publisher","first-page":"628","DOI":"10.5056\/jnm18130","volume":"24","author":"R Shukla","year":"2018","unstructured":"Shukla R, Ghoshal U, Ranjan P, Ghoshal UC. Expression of toll-like receptors, pro-, and antiinflammatory cytokines in relation to gut microbiota in irritable bowel syndrome: The evidence for its micro-organic basis. J Neurogastroenterol Motil. 2018;24:628\u201342.","journal-title":"J Neurogastroenterol Motil"},{"key":"430_CR35","doi-asserted-by":"crossref","unstructured":"Aguilar-Olivos NE, Carrillo-C\u00f3rdova D, Oria-Hern\u00e1ndez J, S\u00e1nchez-Valle V, Ponciano-Rodr\u00edguez G, Ram\u00edrez-Jaramillo M, et al. The nuclear receptor FXR, but not LXR, up-regulates bile acid transporter expression in non-alcoholic fatty liver disease. Ann Hepatol. 2015;14:487\u201393.","DOI":"10.1016\/S1665-2681(19)31170-6"},{"key":"430_CR36","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1159\/000450982","volume":"35","author":"A Wahlstr\u00f6m","year":"2017","unstructured":"Wahlstr\u00f6m A, Kovatcheva-Datchary P, St\u00e5hlman M, B\u00e4ckhed F, Marschall H-U. Crosstalk between bile acids and gut microbiota and its impact on farnesoid X REceptor Signalling. Dig Dis. 2017;35:246\u201350.","journal-title":"Dig Dis"},{"key":"430_CR37","doi-asserted-by":"publisher","unstructured":"Albert I, Tanaka N, Li F, Xie C, Krausz KW, Amin SG, et al. Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. J Clin Invest. 2014;125. https:\/\/doi.org\/10.1172\/jci76738.","DOI":"10.1172\/jci76738"},{"key":"430_CR38","doi-asserted-by":"publisher","first-page":"413","DOI":"10.2337\/dc17-2108","volume":"41","author":"Y Heianza","year":"2018","unstructured":"Heianza Y, Sun D, Smith SR, Bray GA, Sacks FM, Qi L. Changes in gut microbiota-related metabolites and long-term successful weight loss in response to weight-loss diets: The POUNDS Lost trial. Diabetes Care. 2018;41:413\u20139.","journal-title":"Diabetes Care"},{"key":"430_CR39","doi-asserted-by":"publisher","unstructured":"Canfora EE, Meex RCR, Venema K, Blaak EE. Gut microbial metabolites in obesity, NAFLD and T2DM. Nat Rev Endocrinol. 2019. https:\/\/doi.org\/10.1038\/s41574-019-0156-z.","DOI":"10.1038\/s41574-019-0156-z"},{"key":"430_CR40","first-page":"199","volume":"9","author":"P Prinz","year":"2015","unstructured":"Prinz P, Hofmann T, Ahnis A, Elbelt U, Goebel-Stengel M, Klapp BF, et al. Plasma bile acids show a positive correlation with body mass index and are negatively associated with cognitive restraint of eating in obese patients. Front Neurosci. 2015;9:199.","journal-title":"Front Neurosci"},{"key":"430_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/srep19076","volume":"6","author":"Y Chen","year":"2016","unstructured":"Chen Y, Liu Y, Zhou R, Chen X, Wang C, Tan X, et al. Associations of gut-flora-dependent metabolite trimethylamine-N-oxide, betaine and choline with non-alcoholic fatty liver disease in adults. Sci Rep. 2016;6:19076.","journal-title":"Sci Rep"},{"key":"430_CR42","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.jbiosc.2014.03.001","volume":"118","author":"X Gao","year":"2014","unstructured":"Gao X, Liu X, Xu J, Xue C, Xue Y, Wang Y. Dietary trimethylamine N-oxide exacerbates impaired glucose tolerance in mice fed a high fat diet. J Biosci Bioeng. 2014;118:476\u201381.","journal-title":"J Biosci Bioeng"},{"key":"430_CR43","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/nm.3145","volume":"19","author":"RA Koeth","year":"2013","unstructured":"Koeth RA, Wang Z, Levison BS, Buffa JA, Org E, Sheehy BT, et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med. 2013;19:576\u201385.","journal-title":"Nat Med"},{"key":"430_CR44","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.metabol.2010.03.006","volume":"60","author":"SC Kalhan","year":"2011","unstructured":"Kalhan SC, Guo L, Edmison J, Dasarathy S, McCullough AJ, Hanson RW, et al. Plasma metabolomic profile in nonalcoholic fatty liver disease. Metabolism. 2011;60:404\u201313.","journal-title":"Metabolism"},{"key":"430_CR45","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.taap.2013.01.022","volume":"268","author":"AD Lake","year":"2013","unstructured":"Lake AD, Novak P, Shipkova P, Aranibar N, Robertson D, Reily MD, et al. Decreased hepatotoxic bile acid composition and altered synthesis in progressive human nonalcoholic fatty liver disease. Toxicol Appl Pharmacol. 2013;268:132\u201340.","journal-title":"Toxicol Appl Pharmacol"},{"key":"430_CR46","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0151829","volume":"11","author":"M Mouzaki","year":"2016","unstructured":"Mouzaki M, Wang AY, Bandsma R, Comelli EM, Arendt BM, Zhang L, et al. Bile acids and dysbiosis in non-alcoholic fatty liver disease. PLoS ONE. 2016;11:e0151829.","journal-title":"PLoS ONE"},{"key":"430_CR47","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1002\/hep.26093","volume":"57","author":"L Zhu","year":"2013","unstructured":"Zhu L, Baker SS, Gill C, Liu W, Alkhouri R, Baker RD, et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology. 2013;57:601\u20139.","journal-title":"Hepatology"},{"key":"430_CR48","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000002630","volume":"95","author":"R Jamali","year":"2016","unstructured":"Jamali R, Arj A, Razavizade M, Aarabi MH. Prediction of nonalcoholic fatty liver disease via a novel panel of serum adipokines. Medicine (Baltimore). 2016;95:e2630.","journal-title":"Medicine (Baltimore)"}],"container-title":["International Journal of Obesity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41366-019-0430-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41366-019-0430-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41366-019-0430-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T18:23:39Z","timestamp":1630693419000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41366-019-0430-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,6]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["430"],"URL":"https:\/\/doi.org\/10.1038\/s41366-019-0430-0","relation":{},"ISSN":["0307-0565","1476-5497"],"issn-type":[{"value":"0307-0565","type":"print"},{"value":"1476-5497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,6]]},"assertion":[{"value":"15 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}